Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 2/20 | 0.36 |
| ▸ | PYGM | P11217 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060847 | 0.82 | GRIN2B (0.40) | MEN1GAAMAPTKMT2A | |
| SCHEMBL2060961 | 0.72 | GRIN2B (0.57) | KDM4EKMT2A | |
| SCHEMBL521848 | 0.71 | CRBN (0.51) | CA9CRBNDDB1IKZF3PYGL | |
| SCHEMBL3597873 | 0.69 | CA9 (0.40) | CA9CRBNKDM4EMEN1GAA | |
| SCHEMBL2062390 | 0.68 | KDM4E (0.34) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL3598181 | 0.68 | TRPV1 (0.47) | CA9CRBNKDM4EMEN1GAA | |
| SCHEMBL7791600 | 0.67 | CRBN (0.49) | CRBNDDB1IKZF3PYGLPYGM | |
| SCHEMBL25585818 | 0.65 | RIPK1 (0.42) | CRBNDDB1PYGLPYGMRIPK1 | |
| SCHEMBL3584900 | 0.65 | CA9 (0.43) | CA9KDM4EMEN1GAAMAPT | |
| SCHEMBL25707308 | 0.65 | RIPK1 (0.47) | CRBNDDB1PYGLPYGMRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CA9 1403/4885CRBN 1739/4885KDM4E 729/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | CA9 1403/4885CRBN 1739/4885KDM4E 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.